There is no real competition here. Baxter's 20% IG for sc use has been many years in development and will compete with Behrings's Hizentra, another 20% IG for sc use. I imagine there are some immunodeficient patient's who want home based treatment who can't use Hyqvia, for whatever reason. And Baxter wasn't going to shut down a new product that was almost completely through trials when Hyqvia was approved. It costs them little to have this product available but it won't compete, really. Why?
- It has to be given in multiple sites (up to 4) simultaneously twice per month.
- It has a higher incidence of local reactions, and if the difficulty in administering it leads to noncompliance, there will be less protection and more infections.
News 
Market Data 
Discover 
